AcquisitionOther
LAVA Therapeutics NV acquired LAVA have been satisfied. All validly tendered shares are expected to be accepted
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
LAVA Therapeutics NV -> LAVA have been satisfied. All validly tendered shares are expected to be accepted
is a biopharmaceutical company that has developed several clinical-stage bispecific gamma delta T cell engagers using its proprietary Gammabody® platform, including JNJ-89853413, targeting CD33 and hematologic cancers (NCT06618001), partnered with Johnson
Open source record (SEC) ↗